WASHINGTON (AP) — The Supreme Court says the makers of a name brand drug have to correct a patent that could hinder the approval of a generic drug.
The high court on Tuesday agreed with a court decision that forced Novo Dordisk A/S to correct the patent for repaglinide, which is marketed as the diabetes drug Prandin.
Generic drug maker Caraco Pharmaceutical Laboratories, Ltd., wants to make a generic version. But Novo had its patent description revised and made broader, which blocks Caraco's generic application. A federal judge ruled that Novo's description was too broad and ordered them to change it, although that decision was overturned by the U.S. Court of Appeals for the Federal Circuit.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
